Products
Ertumaxomab Biosimilar Bispecific Biologic (CD3 × ERBB2) for Research
Cat No.: GMP-Bios-INN-845
Pre-made Ertumaxomab benchmark antibody (Bispecific, anti-CD3E;ERBB2/HER2 therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-845-1mg | 1mg | |
| GMP-Bios-INN-845-10mg | 10mg | |
| GMP-Bios-INN-845-100mg | 100mg | |
| GMP-Bios-INN-845-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Ertumaxomab Biosimilar, Bispecific, Anti-Cd3E;Erbb2 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody |
| INN Name | Ertumaxomab |
| Target | CD3E;ERBB2/HER2 |
| Format | Bispecific |
| Derivation | |
| Species Reactivity | |
| CH1 Isotype | |
| VD LC | |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | Triomab® (Trifunctional Ab) |
